Biotest Future Growth
Future criteria checks 4/6
Biotest is forecast to grow earnings and revenue by 94.1% and 11.6% per annum respectively while EPS is expected to grow by 94.1% per annum.
Key information
94.1%
Earnings growth rate
94.1%
EPS growth rate
| Biotechs earnings growth | 37.0% |
| Revenue growth rate | 11.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 28 Apr 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 712 | 59 | 26 | N/A | 1 |
| 12/31/2024 | 636 | -4 | -30 | N/A | 1 |
| 12/31/2023 | 568 | -74 | -33 | N/A | 1 |
| 3/31/2023 | 517 | -47 | -127 | -98 | N/A |
| 12/31/2022 | 516 | -32 | -70 | -40 | N/A |
| 9/30/2022 | 505 | -69 | -4 | 14 | N/A |
| 6/30/2022 | 511 | -65 | 30 | 49 | N/A |
| 3/31/2022 | 512 | -54 | 51 | 69 | N/A |
| 12/31/2021 | 516 | -63 | 16 | 34 | N/A |
| 9/30/2021 | 514 | -28 | -3 | 24 | N/A |
| 6/30/2021 | 507 | -33 | -32 | -5 | N/A |
| 3/31/2021 | 507 | -35 | -49 | -22 | N/A |
| 12/31/2020 | 484 | -31 | -44 | -17 | N/A |
| 9/30/2020 | 466 | -34 | -74 | -40 | N/A |
| 6/30/2020 | 459 | -24 | -83 | -49 | N/A |
| 3/31/2020 | 439 | -15 | -70 | -36 | N/A |
| 12/31/2019 | 419 | -5 | -68 | -34 | N/A |
| 9/30/2019 | 406 | -9 | -74 | -19 | N/A |
| 6/30/2019 | 395 | -3 | -61 | -6 | N/A |
| 3/31/2019 | 390 | -6 | -81 | -26 | N/A |
| 12/31/2018 | 400 | -13 | -105 | -50 | N/A |
| 9/30/2018 | 405 | 18 | -123 | -16 | N/A |
| 6/30/2018 | 409 | 6 | -100 | 6 | N/A |
| 3/31/2018 | 400 | 1 | -92 | 15 | N/A |
| 12/31/2017 | 378 | -16 | -72 | 34 | N/A |
| 9/30/2017 | 257 | -48 | -125 | 8 | N/A |
| 6/30/2017 | 301 | -47 | -141 | -8 | N/A |
| 3/31/2017 | 340 | -29 | -98 | 35 | N/A |
| 12/31/2016 | 408 | 6 | N/A | 66 | N/A |
| 9/30/2016 | 531 | 128 | N/A | 51 | N/A |
| 6/30/2016 | 525 | 52 | N/A | 57 | N/A |
| 3/31/2016 | 526 | 36 | N/A | 44 | N/A |
| 12/31/2015 | 535 | 27 | N/A | 38 | N/A |
| 9/30/2015 | 590 | -88 | N/A | 62 | N/A |
| 6/30/2015 | 606 | 3 | N/A | 54 | N/A |
| 3/31/2015 | 602 | 16 | N/A | 15 | N/A |
| 12/31/2014 | 582 | 19 | N/A | -11 | N/A |
| 9/30/2014 | 543 | 27 | N/A | -26 | N/A |
| 6/30/2014 | 522 | 31 | N/A | -28 | N/A |
| 3/31/2014 | 504 | 30 | N/A | -1 | N/A |
| 12/31/2013 | 501 | 32 | N/A | -7 | N/A |
| 9/30/2013 | 483 | 32 | N/A | 10 | N/A |
| 6/30/2013 | 463 | 29 | N/A | 20 | N/A |
| 3/31/2013 | 451 | 26 | N/A | 21 | N/A |
| 12/31/2012 | 440 | 23 | N/A | 35 | N/A |
| 9/30/2012 | 435 | 20 | N/A | 0 | N/A |
| 6/30/2012 | 429 | 18 | N/A | 66 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIO3D is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).
Earnings vs Market: BIO3D is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BIO3D is expected to become profitable in the next 3 years.
Revenue vs Market: BIO3D's revenue (11.6% per year) is forecast to grow faster than the UK market (4% per year).
High Growth Revenue: BIO3D's revenue (11.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BIO3D's Return on Equity is forecast to be high in 3 years time